Loading quotes...
Forecast
The analysts' average price target is €100.54 (+9.52%). The median is €99.48 (+8.37%).
| Buy |
Â
16 |
| Hold |
Â
10 |
| Sell |
Â
1 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Halozyme achieves over 60% EBITDA margin with lucrative licensing business
Halozyme operates as a highly profitable licensing company that simplifies infusion therapies and, thanks to a licensing model and a high EBITDA margin, generates reliable cash flows. New self‑administration drug technologies and an extensive partner pipeline support further growth, especially amid the trend toward outpatient cancer therapies. As a result, Halozyme presents itself less as a speculative drug developer and more as a cash‑flow‑strong biotech investment. » More on finanzen.net
Halozyme presents tiered licensing growth strategy and strong Q2 results
At the Morgan Stanley Healthcare Conference, Halozyme highlighted record revenue of $308 million for Q2 2024 and accelerated growth in partner products. The company emphasized the diversification of its technologies (ENHANZE, Hypercon, Surf Bio), five new business partnerships in 2024, and optimistic revenue guidance for 2024 as well as long‑term targets through 2028. Management views political risks and tariffs as having little impact, expects further contract signings, and is relying on AI‑driven efficiency, buybacks and selective M&A to strengthen the licensing base. » More on de.investing.com
Halozyme sees growth from subcutaneous delivery
Halozyme reported strong growth at the Wells Fargo Healthcare Conference: revenue in Q2 2024 rose to $481m (+48%) and licensing income exceeded $300m (+50%). The ENHANZE platform is driving commercial switches to subcutaneous formats, and the company is expanding its pipeline with HyperCon, autoinjector technologies and several new partnerships. Management cites patent protection issues, a pending lawsuit with Merck and potential future declines in license royalties as risks, but emphasizes strong free cash flow, room for investment, share buybacks and debt reduction. » More on de.investing.com
Halozyme Therapeutics hits new all-time high at $109.69
Halozyme Therapeutics' stock rose to a record high of $109.69, bringing market capitalization to about $12.4 billion. The shares are up 46.06% over the past 12 months, 54% over the past six months and 60% year-to-date. In the second quarter Halozyme beat expectations with a non-GAAP EPS of $2.28 (expectation $1.81) and revenue of $481 million (expectation $401.27 million), driven by record licensing revenues, after which the full-year guidance was raised. Analysts reacted positively: Citizens slightly raised its price target to $93 with a "market outperform" rating, and H.C. Wainwright reaffirmed "buy" with a $115 target following positive partner data. » More on de.investing.com
Halozyme hits record high of $109.59 after strong quarterly results
Halozyme's stock climbed to an all-time high of $109.59 and is up about 62% year-to-date. In the second quarter the company beat expectations with non-GAAP earnings of $2.28 per share (expectation $1.81) and revenue of $481 million (forecast $401.27 million). Halozyme raised its full-year guidance, attributing the revision to record licensing revenue and robust growth in partner drugs. Several analysts raised estimates or price targets, and one analysis still sees the stock trading below its fair value despite the rally. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 435.22m | 44.17% |
| Gross profit | 362.41m | 42.23% |
| Net profit | 218.11m | 46.07% |
| EBITDA | 292.11m | 40.68% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €10.43bn |
Number of shares | 114.01m |
52-week high/low | €121.74 - €55.63 |
| Dividends | No |
Beta | 0.90 |
P/E ratio | 23.97 |
PEG ratio | -1.70 |
P/B ratio | -207.39 |
P/S ratio | 6.37 |
Company profile
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
| Name | Halozyme Therapeutics |
| CEO | Helen I. Torley |
| Headquarters | San Diego,
ca USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 03/10/2008 |
| Employees | 423 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | HALO |
London Stock Exchange | 0J2O.L |
Frankfurt | RV7.F |
DĂĽsseldorf | RV7.DU |
London | 0J2O.L |
SIX | RV7.SW |
MĂĽnchen | RV7.MU |